Skip To Main Content

Questions?1-833-393-4363

Learn how VABYSMO may help with DME

Man at doctor office

VABYSMO^® improves vision quickly* and delivers a chance for up to 4 months between treatments^†

*On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.

^†After 4 or 6 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response. Dosing may vary.

VABYSMO IMPROVES VISION QUICKLY*

On average, people gained and maintained 11 letters on an eye chart in 1 year (chart)

On average, people gained and maintained 11 letters on an eye chart over 1 year with VABYSMO, similar to aflibercept 2 mg.

After their first treatment, people on average gained 6 letters on an eye chart at 1 month with VABYSMO, similar to aflibercept 2 mg.

VABYSMO helped people maintain their vision through 2-year clinical trials^‡§

^‡VABYSMO was assessed in 2 clinical studies vs aflibercept 2 mg in 1891 people with DME. Both studies demonstrated non-inferiority to aflibercept 2 mg at the primary endpoint, defined as the mean change from baseline in BCVA at year 1.

^§Maintained is defined as not losing 15 letters or more.

EXPLORE A CHANCE FOR UP TO 4 MONTHS INJECTION-FREE^†

Every 1 or 2 or 3 or 4 months graphic

OR

AFTER 6 INITIAL MONTHLY doses, you can go 2 months between treatments.

Although most people from the clinical trials went 3-4 months between injections, this may not be the experience of all people. Your retina specialist may evaluate your disease differently from the methods used in our trials.

In the second year of treatment, most people needed fewer injections with VABYSMO.^¶

^¶After 4 or 6 initial monthly doses, receive a minimum of 6 injections over 2 years (and a maximum of 21). Your retina specialist will determine the dosing schedule that is right for you.

Eye chart (graphic)

Improves vision quickly with results maintained in the second year of treatment*

Two ways (graphic)

The only treatment thought to block 2 causes of DME^#

Calendar (graphic)

Delivers a chance for up to 4 months between treatments,^† so you can do more of what you love

^#VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.

Caretaker Patient Imagery (Nina)

"VABYSMO has given me a second chance."

Nina | VABYSMO Patient

DME New Patient Imagery (Armye)

"After the first injection, I noticed a difference in my vision."*

Armye | VABYSMO Patient

DME New Patient Imagery (Charles)

"I was shocked at how quick VABYSMO was working for me."

Charles | VABYSMO Patient

Patient experiences may vary. Patients compensated by Genentech.

WATCH THEIR FULL STORIES

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.